{"gene":"APOC2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1977,"finding":"The C-terminal region of apoC-II (residues 55–78) is both necessary and sufficient for maximal activation of lipoprotein lipase (LPL); the fragment 60–78 activates LPL ~4-fold, fragment 55–78 activates ~12-fold (comparable to intact apoC-II at ~13-fold), while removal of the three C-terminal residues (Gly-Glu-Glu) abolishes >95% of activation activity.","method":"In vitro LPL activation assay using cyanogen bromide fragments and synthetic peptides of apoC-II","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro assay with multiple synthetic fragments and mutagenesis-equivalent deletions; foundational study with >100 citations","pmids":["270715"],"is_preprint":false},{"year":1977,"finding":"ApoC-II has a primary structure of 78 amino acid residues (lacking cysteine, cystine, and histidine), establishing it as the activator protein of LPL in very low density lipoproteins.","method":"Protein purification, cyanogen bromide digestion, and sequential amino acid sequencing of tryptic/CNBr peptides","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct protein sequencing, foundational structural determination, >100 citations","pmids":["194244"],"is_preprint":false},{"year":1973,"finding":"During alimentary lipemia, apoC-II (the LPL activator protein) transfers specifically from HDL to chylomicrons, with chylomicron apoC-II concentration directly proportional to particle diameter; HDL apoC-II decreases correspondingly, demonstrating a dynamic exchange of apoC-II between lipoprotein classes.","method":"Ultracentrifugal fractionation and polyacrylamide gel electrophoresis of lipoprotein subfractions from human subjects pre- and post-fat meal","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical fractionation in human subjects, replicated across multiple time points, >500 citations","pmids":["4345202"],"is_preprint":false},{"year":1984,"finding":"The cDNA for apoC-II was isolated and sequenced, identifying a 22-amino-acid signal peptide and determining relative liver mRNA abundance, establishing the molecular basis for apoC-II biosynthesis.","method":"cDNA cloning, nucleotide sequencing, and Northern blot mRNA quantification","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — direct cDNA sequencing and mRNA abundance measurement; >100 citations","pmids":["6328445"],"is_preprint":false},{"year":1985,"finding":"ApoC-II (along with apoC-I and apoC-III isoforms) inhibits the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver; this inhibition is independent of apoE and applies to both chylomicron remnants and VLDL remnants. Preferential loss of apoC-II during remnant formation may regulate termination of triglyceride hydrolysis.","method":"Isolated perfused rat liver assay with exogenous addition of individual human C apolipoproteins to chylomicrons and VLDL remnants","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — reconstituted perfused organ system with defined apolipoprotein additions; >250 citations","pmids":["4020294"],"is_preprint":false},{"year":1991,"finding":"ApoC-II inhibits apoE-dependent cellular uptake and degradation of triglyceride-rich lipoproteins via the LDL receptor pathway; the apoE:apoC ratio on the lipoprotein surface determines the extent of receptor-mediated uptake. ApoC-II does not affect LDL (apoB-100-mediated) metabolism significantly, demonstrating specificity for the apoE-dependent interaction.","method":"Cultured human skin fibroblast uptake/degradation assays using VLDL and IDL with exogenous recombinant apoE-3 and individual apoC species; monoclonal antibody blocking of apoB-100 vs. apoE","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — cell-based reconstitution with defined protein additions, antibody-blocking specificity controls; >200 citations","pmids":["1917954"],"is_preprint":false},{"year":2001,"finding":"Farnesoid X receptor (FXR) directly induces APOC2 transcription by binding two FXR response elements within hepatic control regions (HCR-1 and HCR-2) located 11 kb and 22 kb upstream of the apoC-II transcription start site; FXR/RXR heterodimers bind these elements by EMSA, and luciferase reporter assays confirm transactivation. In vivo, hepatic apoC-II mRNA increases in mice fed cholic acid (an FXR ligand), and this induction is absent in FXR-null mice, linking bile acid signaling to plasma triglyceride lowering via apoC-II.","method":"Suppression subtractive hybridization, retroviral FXR expression in HepG2 cells, EMSA with recombinant FXR/RXR, luciferase reporter assays, mouse dietary cholic acid feeding, FXR knockout mice","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (EMSA, reporter assay, in vivo KO model); >250 citations","pmids":["11579204"],"is_preprint":false},{"year":2001,"finding":"ABCA1 mediates cholesterol and phospholipid efflux using apoC-II (as well as apoA-I, apoA-II, apoA-IV, apoC-I, apoC-III, apoE) as acceptors; apoC-II promotes greater than 3-fold increase in lipid efflux from ABCA1-expressing cells compared to controls, indicating apoC-II can serve as a lipid acceptor for ABCA1-mediated reverse cholesterol transport.","method":"Stable transfection of ABCA1-GFP in HeLa cells, cholesterol and phospholipid efflux assays, specific binding assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — clean cellular assay with defined protein acceptors; single lab but multiple apolipoproteins tested as controls; >250 citations","pmids":["11162594"],"is_preprint":false},{"year":2001,"finding":"ApoC-II forms amyloid fibers in lipid-free solutions under physiological conditions; macromolecular crowding (inert polymer dextran T10) significantly accelerates amyloid formation rate and extent via nonspecific volume exclusion, without altering secondary structure, fiber morphology, or dye-binding capacity of the fibers.","method":"Solution turbidity, thioflavin T reactivity, sedimentation assays, analytical ultracentrifugation, secondary structure analysis; quantitative modeling of volume exclusion","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biophysical assays with quantitative mechanistic modeling; >200 citations","pmids":["11751863"],"is_preprint":false},{"year":2002,"finding":"The APOE/C-I/C-IV/C-II gene cluster is transcriptionally regulated by liver X receptors (LXRα/β) in macrophages; LXR/RXR ligands induce apoC-II mRNA 2–14-fold, this induction requires the LXR response elements in multienhancers ME.1 and ME.2 of the apoC-II promoter-reporter, and is abolished in LXRα/β double-null macrophages. ApoC-II protein co-localizes with macrophages within murine arterial lesions.","method":"Microarray, Northern blot, LXRα/β knockout murine macrophages, luciferase reporter assays with ME.1/ME.2 enhancer elements, immunohistochemistry of atherosclerotic lesions","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — genetic KO validation plus reporter assays and in vivo localization; >190 citations","pmids":["12032151"],"is_preprint":false},{"year":2017,"finding":"APOC2 knockout zebrafish (apoc2−/−) exhibit deficient plasma cholesterol esterification: significantly elevated free cholesterol to cholesterol ester ratio (FC/CE) compared to wild type, accompanied by dramatically decreased hepatic LCAT expression and apoA-I expression. This defect persists on low-fat diet even when triglycerides normalize, and is recapitulated in human FCS patients with APOC2 or LPL deficiency, revealing a novel link between LPL cofactor activity and LCAT-mediated cholesterol esterification.","method":"apoc2 knockout zebrafish, plasma FC/CE measurements, in situ hybridization, qPCR of lcat and apoA-I, LCAT activity assay in human FCS patient plasma, lipidomics of chylomicron-depleted fractions","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genetic KO model plus human patient validation with orthogonal biochemical assays","pmids":["28107429"],"is_preprint":false},{"year":2020,"finding":"ApoC2 is an obligatory activator of LPL for plasma triglyceride hydrolysis; CRISPR/Cas9 deletion of Apoc2 in golden Syrian hamsters causes severe hypertriglyceridemia that cannot be corrected by lipid-lowering medications but is fully reversed by AAV-hApoC2 gene therapy, demonstrating that ApoC2 is essential and sufficient for LPL-mediated triglyceride metabolism in a mammalian model.","method":"CRISPR/Cas9 Apoc2 knockout hamster, AAV-hApoC2 gene therapy rescue, lipid profile measurements, diet intervention, neonatal serum infusion rescue","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 1–2 — complete genetic KO with defined molecular rescue in mammalian model","pmids":["32562799"],"is_preprint":false},{"year":2020,"finding":"miR-1275 directly targets the 3′ UTR of ApoC2 mRNA in macrophages, suppressing ApoC2 protein expression; ApoC2 knockdown inhibits macrophage foam cell formation by reducing ox-LDL uptake, and ApoC2 overexpression promotes foam cell formation, placing ApoC2 downstream of miR-1275 in macrophage lipid accumulation relevant to ischemic stroke pathogenesis.","method":"Dual-luciferase reporter assay, miRNA microarray, quantitative RT-PCR, THP-1 macrophage foam cell assay with ox-LDL uptake measurement, siRNA knockdown","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2–3 — luciferase reporter plus functional cellular assays; single lab","pmids":["31935511"],"is_preprint":false},{"year":2020,"finding":"miR-4510 directly targets APOC2 (confirmed by luciferase reporter assay); APOC2 knockdown in GIST cells suppresses cell proliferation, migration, and invasion, reduces AKT and ERK1/2 phosphorylation, and decreases MMP2/MMP9 expression, identifying APOC2 as a pro-tumorigenic factor acting through PI3K/AKT and MAPK/ERK signaling in gastrointestinal stromal tumors.","method":"Luciferase reporter assay, siRNA knockdown of APOC2, cell proliferation/migration/invasion assays, Western blotting for p-AKT, p-ERK1/2, MMP2, MMP9","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 — luciferase confirmation plus functional KD phenotype with pathway readouts; single lab","pmids":["31975384"],"is_preprint":false},{"year":2023,"finding":"ApoC-II's C-terminal α-helix binds to regions of LPL surrounding the catalytic pocket (lid-anchoring structures), overlapping with the ANGPTL4 binding site on LPL. Unlike ANGPTL4, which destabilizes LPL's lid-anchoring regions and promotes irreversible unfolding, APOC2 binding increases LPL thermal stability and protects these regions from unfolding, providing a molecular mechanism for APOC2-mediated LPL activation through conformational stabilization of the active site.","method":"Hydrogen-deuterium exchange mass spectrometry (HDX-MS) with thermal stability assays comparing APOC2 vs. ANGPTL4 binding to LPL","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — structural/biophysical HDX-MS with direct comparison of activator vs. inhibitor binding to same site; mechanistically rigorous","pmids":["37094117"],"is_preprint":false},{"year":2022,"finding":"APOC2 expression level defines distinct alveolar macrophage superclusters (families) in human bronchoalveolar lavage; differential APOC2/IFI27 expression distinguishes four AM supercluster identities, each containing functionally specialized subclusters, indicating APOC2 marks a transcriptionally and functionally distinct state in resident lung macrophages.","method":"Single-cell RNA sequencing of 113,213 bronchoalveolar lavage cells, TotalSeq protein surface marker validation, projection of external AM datasets","journal":"Life science alliance","confidence":"Low","confidence_rationale":"Tier 3 — scRNA-seq classification without direct functional manipulation of APOC2 in macrophages","pmids":["35820705"],"is_preprint":false},{"year":2022,"finding":"In bovine adipocytes, miR-107 directly targets APOC2 (confirmed by luciferase reporter assay); APOC2 knockdown (siRNA) suppresses adipocyte differentiation and lipid droplet accumulation, while miR-107 overexpression (which reduces APOC2) similarly inhibits adipogenesis, establishing APOC2 as a positive regulator of bovine adipocyte differentiation and lipogenesis downstream of miR-107.","method":"Luciferase reporter assay, agomiR/antiagomiR transfection, siRNA-APOC2 knockdown, Oil Red O staining, CCK-8, EdU proliferation assay, RT-qPCR, Western blotting","journal":"Genes","confidence":"Medium","confidence_rationale":"Tier 2–3 — luciferase confirmation plus functional KD in bovine cells; single lab, non-human model","pmids":["36011378"],"is_preprint":false},{"year":2025,"finding":"FXR activation upregulates ApoC2 expression in beige adipocytes (but not mature white adipocytes); ApoC2 overexpression in preadipocytes and beige adipocytes increases UCP1 and PGC1α expression, while FXR knockdown reduces ApoC2 along with UCP1, PGC1α, and PRDM16, placing ApoC2 downstream of FXR in a pathway promoting white adipose tissue browning and thermogenesis.","method":"FXR agonist (farnesol) treatment, siRNA knockdown of FXR and RXRα, ApoC2 overexpression in preadipocytes and beige adipocytes, Western blotting and RT-qPCR for beige/thermogenic markers, cold-exposure mouse model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function in cells plus in vivo cold exposure; single lab, mechanism partially established","pmids":["39798876"],"is_preprint":false},{"year":2025,"finding":"APOC2 knockdown in clear cell renal cell carcinoma (ccRCC) cell lines suppresses proliferation, colony formation, migration, and invasion while promoting apoptosis; silencing APOC2 reduces phosphorylation of JAK1/2 and STAT3 without affecting total protein levels, and the STAT3 agonist Colivelin partially rescues viability and apoptosis caused by APOC2 knockdown, indicating APOC2 promotes ccRCC progression at least partly through JAK-STAT pathway activation.","method":"siRNA knockdown of APOC2 in ccRCC cell lines, proliferation/colony/migration/invasion/apoptosis assays, Western blotting for p-JAK1/2 and p-STAT3, functional rescue with Colivelin (STAT3 agonist), gene set enrichment analysis","journal":"Current issues in molecular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 — KD with defined pathway readout and partial rescue; single lab, cellular context non-canonical for APOC2","pmids":["41296440"],"is_preprint":false}],"current_model":"ApoC-II (APOC2) is a 78-residue plasma apolipoprotein whose C-terminal α-helix (residues ~55–78) directly binds and stabilizes the lid-anchoring regions of lipoprotein lipase (LPL), increasing LPL thermal stability and activating triglyceride hydrolysis of VLDL and chylomicrons; it also inhibits apoE-dependent hepatic remnant uptake via the LDL receptor, transfers dynamically between HDL and triglyceride-rich lipoproteins during alimentary lipemia, is transcriptionally induced by FXR (via hepatic control region response elements) and by LXR in macrophages, forms amyloid fibers under crowded conditions, and has emerging roles in cholesterol esterification, adipose browning (via FXR-ApoC2-UCP1 axis), and cellular signaling (JAK-STAT) in non-classical contexts."},"narrative":{"teleology":[{"year":1973,"claim":"Establishing that apoC-II is not statically bound to one lipoprotein class but dynamically redistributes from HDL to chylomicrons during fat absorption answered how the activator reaches its substrate particles in vivo.","evidence":"Ultracentrifugal fractionation and gel electrophoresis of human lipoproteins pre- and post-fat meal","pmids":["4345202"],"confidence":"High","gaps":["Mechanism governing transfer kinetics and directionality was not defined","Whether transfer is passive equilibrium or protein-mediated was not distinguished"]},{"year":1977,"claim":"Determination of apoC-II's 78-residue primary structure and mapping of the LPL-activating domain to the C-terminal helix (residues 55–78, with terminal Gly-Glu-Glu essential) resolved which portion of the protein is functionally critical and established the minimal activating unit.","evidence":"Protein sequencing plus in vitro LPL activation assays with synthetic and CNBr-derived peptide fragments","pmids":["194244","270715"],"confidence":"High","gaps":["Structural basis of how the C-terminal helix contacts LPL was unknown","Role of the N-terminal domain in lipid binding versus activation was not separated"]},{"year":1985,"claim":"Showing that apoC-II inhibits hepatic uptake of triglyceride-rich lipoprotein remnants—independent of its LPL-activating role—revealed a second function: modulating receptor-mediated clearance by competing with apoE on the particle surface.","evidence":"Perfused rat liver assay with exogenous addition of purified apoC-II to remnant particles; cell-based fibroblast uptake assays with antibody blocking (1991 confirmation)","pmids":["4020294","1917954"],"confidence":"High","gaps":["Whether inhibition is purely steric displacement of apoE or involves receptor conformational effects was not resolved","Relative in vivo contribution of uptake inhibition versus LPL activation to triglyceride homeostasis was not quantified"]},{"year":2001,"claim":"Identification of FXR-responsive elements in the apoC-II hepatic control regions and LXR-responsive multienhancers in macrophages established how bile acid and oxysterol signaling transcriptionally control APOC2 expression in distinct cell types.","evidence":"EMSA, luciferase reporters, FXR-null mice with dietary cholic acid (FXR); LXRα/β double-KO macrophages with ligand treatment (LXR)","pmids":["11579204","12032151"],"confidence":"High","gaps":["Quantitative contribution of FXR versus LXR to circulating apoC-II levels in humans was not determined","Post-transcriptional regulation was not addressed"]},{"year":2001,"claim":"The discovery that lipid-free apoC-II readily forms amyloid fibrils under physiological conditions—accelerated by macromolecular crowding—raised the question of whether apoC-II amyloidosis occurs in vivo and whether lipid dissociation is a pathogenic event.","evidence":"Thioflavin T fluorescence, turbidity, analytical ultracentrifugation, and quantitative crowding modeling","pmids":["11751863"],"confidence":"High","gaps":["No in vivo evidence that apoC-II amyloid deposits contribute to disease","Whether lipoprotein binding constitutively suppresses amyloid nucleation was not tested"]},{"year":2017,"claim":"Zebrafish apoc2 knockouts revealed an unexpected requirement for apoC-II in LCAT-mediated cholesterol esterification, extending its metabolic role beyond triglyceride hydrolysis and linking it to HDL maturation.","evidence":"CRISPR apoc2-KO zebrafish with plasma FC/CE ratio measurement, qPCR of lcat/apoA-I, validated in human familial chylomicronemia syndrome patients","pmids":["28107429"],"confidence":"High","gaps":["Whether the cholesterol esterification defect is a direct apoC-II effect or secondary to chronic hypertriglyceridemia was not resolved","Mechanism linking apoC-II to lcat transcription was not identified"]},{"year":2020,"claim":"CRISPR-generated Apoc2-knockout hamsters confirmed apoC-II as the indispensable LPL cofactor in a mammalian model: severe hypertriglyceridemia was refractory to lipid-lowering drugs but fully corrected by AAV-hApoC2 gene therapy, providing proof-of-concept for gene-replacement treatment.","evidence":"Apoc2-KO hamster model with AAV-hApoC2 rescue, lipid profiling, dietary and pharmacological interventions","pmids":["32562799"],"confidence":"High","gaps":["Long-term safety and durability of AAV-mediated correction were not assessed","Effect of gene therapy on cholesterol esterification phenotype was not examined"]},{"year":2023,"claim":"HDX-MS revealed the structural mechanism of LPL activation: apoC-II's C-terminal helix binds LPL's lid-anchoring regions overlapping the ANGPTL4 inhibitory site, stabilizing the catalytic pocket against thermal unfolding—explaining why apoC-II and ANGPTL4 act as opposing regulators at the same site.","evidence":"Hydrogen-deuterium exchange mass spectrometry comparing apoC-II and ANGPTL4 binding to LPL, with thermal stability assays","pmids":["37094117"],"confidence":"High","gaps":["Full atomic-resolution co-structure of the apoC-II–LPL complex is not yet available","Whether additional LPL-binding partners modulate the apoC-II versus ANGPTL4 competition in vivo is unknown"]},{"year":2025,"claim":"Placing apoC-II downstream of FXR in beige adipocytes as a promoter of UCP1/PGC1α expression expanded its biology to thermogenesis, while evidence in cancer cells suggested non-canonical JAK-STAT signaling roles, raising the question of whether apoC-II has cell-autonomous signaling functions distinct from lipoprotein metabolism.","evidence":"FXR agonist treatment and siRNA in beige adipocytes with thermogenic marker readouts; APOC2 knockdown in ccRCC cells with p-JAK1/2 and p-STAT3 Western blots and STAT3-agonist rescue","pmids":["39798876","41296440"],"confidence":"Medium","gaps":["Whether apoC-II acts as a secreted autocrine/paracrine ligand or intracellularly in these contexts is unknown","JAK-STAT activation mechanism—direct receptor engagement versus indirect lipid signaling—is not defined","Independent replication of non-canonical signaling roles is needed"]},{"year":null,"claim":"A high-resolution co-crystal or cryo-EM structure of the apoC-II–LPL complex is still lacking, the receptor or signaling mechanism underlying apoC-II's reported cell-autonomous effects in non-hepatic tissues remains unidentified, and whether apoC-II amyloid formation has pathological significance in vivo is unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic co-structure of apoC-II–LPL complex","No identified receptor for putative cell-autonomous apoC-II signaling","In vivo relevance of apoC-II amyloidosis not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,5,14]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,7]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,11,14]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,2,4,11]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,4,5,10,11,14]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[2,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,9,17]}],"complexes":[],"partners":["LPL","ANGPTL4","APOE","ABCA1","FXR","LCAT"],"other_free_text":[]},"mechanistic_narrative":"Apolipoprotein C-II is a 78-residue exchangeable apolipoprotein that serves as the obligatory cofactor for lipoprotein lipase (LPL)-mediated hydrolysis of triglycerides in VLDL and chylomicrons. Its C-terminal α-helix (residues 55–78) binds LPL's lid-anchoring regions near the catalytic pocket, increasing LPL thermal stability and protecting against ANGPTL4-induced unfolding, thereby activating triglyceride hydrolysis; the terminal Gly-Glu-Glu residues are critical for this activation [PMID:270715, PMID:37094117]. ApoC-II transfers dynamically from HDL to triglyceride-rich lipoproteins during alimentary lipemia, inhibits apoE-dependent hepatic remnant uptake via the LDL receptor pathway, and is transcriptionally induced by FXR in liver and LXR in macrophages [PMID:4345202, PMID:1917954, PMID:11579204, PMID:12032151]. Genetic ablation in hamsters causes severe hypertriglyceridemia fully rescued by AAV-delivered human APOC2, and loss of APOC2 in zebrafish additionally impairs LCAT-mediated cholesterol esterification, revealing roles beyond triglyceride catabolism [PMID:32562799, PMID:28107429]."},"prefetch_data":{"uniprot":{"accession":"P02655","full_name":"Apolipoprotein C-II","aliases":["Apolipoprotein C2"],"length_aa":101,"mass_kda":11.3,"function":"Component of chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. Both proapolipoprotein C-II and apolipoprotein C-II can activate lipoprotein lipase. In normolipidemic individuals, it is mainly distributed in the HDL, whereas in hypertriglyceridemic individuals, predominantly found in the VLDL and LDL","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02655/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOC2","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOC2","total_profiled":1310},"omim":[{"mim_id":"615947","title":"HYPERLIPOPROTEINEMIA, TYPE ID","url":"https://www.omim.org/entry/615947"},{"mim_id":"613230","title":"PEPTIDASE D; PEPD","url":"https://www.omim.org/entry/613230"},{"mim_id":"612773","title":"BASAL CELL ADHESION MOLECULE; BCAM","url":"https://www.omim.org/entry/612773"},{"mim_id":"612757","title":"GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED HIGH DENSITY LIPOPROTEIN-BINDING PROTEIN 1; GPIHBP1","url":"https://www.omim.org/entry/612757"},{"mim_id":"611998","title":"cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 3; CREB3L3","url":"https://www.omim.org/entry/611998"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":8987.5}],"url":"https://www.proteinatlas.org/search/APOC2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02655","domains":[{"cath_id":"1.20.5","chopping":"64-89","consensus_level":"medium","plddt":61.6608,"start":64,"end":89}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02655","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02655-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02655-F1-predicted_aligned_error_v6.png","plddt_mean":65.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOC2","jax_strain_url":"https://www.jax.org/strain/search?query=APOC2"},"sequence":{"accession":"P02655","fasta_url":"https://rest.uniprot.org/uniprotkb/P02655.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02655/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02655"}},"corpus_meta":[{"pmid":"22239554","id":"PMC_22239554","title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.","date":"2012","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22239554","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8062276","id":"PMC_8062276","title":"The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8062276","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2892779","id":"PMC_2892779","title":"Apolipoprotein gene cluster on chromosome 19. Definite localization of the APOC2 gene and the polymorphic Hpa I site associated with type III hyperlipoproteinemia.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2892779","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29371683","id":"PMC_29371683","title":"DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease.","date":"2018","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29371683","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35820705","id":"PMC_35820705","title":"ScRNA-seq expression of IFI27 and APOC2 identifies four alveolar macrophage superclusters in healthy BALF.","date":"2022","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/35820705","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28201738","id":"PMC_28201738","title":"A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis.","date":"2017","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28201738","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32562799","id":"PMC_32562799","title":"ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: A rodent model rescued from neonatal death.","date":"2020","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/32562799","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1763885","id":"PMC_1763885","title":"The human chromosome 19 linkage group FUT1 (H), FUT2 (SE), LE, LU, PEPD, C3, APOC2, D19S7 and D19S9.","date":"1991","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1763885","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17192963","id":"PMC_17192963","title":"Preimplantation genetic diagnosis for myotonic dystrophy type 1: detection of crossover between the gene and the linked marker APOC2.","date":"2007","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/17192963","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26772541","id":"PMC_26772541","title":"A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitis.","date":"2016","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26772541","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2907851","id":"PMC_2907851","title":"The chromosome 19 linkage group LDLR, C3, LW, APOC2, LU, SE in man.","date":"1988","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2907851","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2591962","id":"PMC_2591962","title":"Recombination events that locate myotonic dystrophy distal to APOC2 on 19q.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2591962","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37094117","id":"PMC_37094117","title":"Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37094117","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25172036","id":"PMC_25172036","title":"Apolipoprotein C-II Tuzla: a novel large deletion in APOC2 caused by Alu-Alu homologous recombination in an infant with apolipoprotein C-II deficiency.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25172036","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31975384","id":"PMC_31975384","title":"miR-4510 acts as a tumor suppressor in gastrointestinal stromal tumor by targeting APOC2.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31975384","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8471544","id":"PMC_8471544","title":"Genetic variation of microsatellite markers D1S117, D6S89, D11S35, APOC2, and D21S168 in the Spanish population.","date":"1993","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8471544","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32802915","id":"PMC_32802915","title":"AAV-Mediated ApoC2 Gene Therapy: Reversal of Severe Hypertriglyceridemia and Rescue of Neonatal Death in ApoC2-Deficient Hamsters.","date":"2020","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/32802915","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28107429","id":"PMC_28107429","title":"Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28107429","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8001915","id":"PMC_8001915","title":"Genetic studies on the Senegal population. II. Polymorphisms of the plasma proteins F13A, F13B, ORM1, AHSG, C6, C7, and APOC2.","date":"1994","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/8001915","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3198115","id":"PMC_3198115","title":"Segregation of linked probes to myotonic dystrophy in a family demonstrating that 152 and APOC2 are on the same side of DM on 19q.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3198115","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31935511","id":"PMC_31935511","title":"Blood miR-1275 is associated with risk of ischemic stroke and inhibits macrophage foam cell formation by targeting ApoC2 gene.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31935511","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32292609","id":"PMC_32292609","title":"Experimental Therapeutics for Challenging Clinical Care of a Patient with an Extremely Rare Homozygous APOC2 Mutation.","date":"2020","source":"Case reports in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32292609","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32280258","id":"PMC_32280258","title":"A Novel APOC2 Mutation in a Colombian Patient with Recurrent Hypertriglyceridemic Pancreatitis.","date":"2020","source":"The application of clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32280258","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36011378","id":"PMC_36011378","title":"MiR-107 Regulates Adipocyte Differentiation and Adipogenesis by Targeting Apolipoprotein C-2 (APOC2) in Bovine.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36011378","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38938447","id":"PMC_38938447","title":"Pancreatitis as a Main Consequence of APOC2-Related Hypertriglyceridemia: The Role of Nonsense and Frameshift Variants.","date":"2024","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38938447","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33129550","id":"PMC_33129550","title":"Sequence analysis of the coding regions of the apolipoprotein C2 (APOC2) gene in Miniature Schnauzers with idiopathic hypertriglyceridemia.","date":"2020","source":"Veterinary journal (London, England : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/33129550","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23470567","id":"PMC_23470567","title":"Apolipoprotein C-II deficiency with no rare variant in the APOC2 gene.","date":"2013","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/23470567","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36690263","id":"PMC_36690263","title":"Comprehensive in-silico analysis of deleterious SNPs in APOC2 and APOA5 and their differential expression in cancer and cardiovascular diseases conditions.","date":"2023","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/36690263","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3047535","id":"PMC_3047535","title":"Presymptomatic testing for myotonic dystrophy by means of the linked DNA marker APOC2.","date":"1988","source":"The Medical journal of Australia","url":"https://pubmed.ncbi.nlm.nih.gov/3047535","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39798876","id":"PMC_39798876","title":"FXR-ApoC2 pathway activates UCP1-mediated thermogenesis by promoting the browning of white adipose tissues.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39798876","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30307897","id":"PMC_30307897","title":"Severe hyperchylomicronemia in two infants with novel APOC2 gene mutation.","date":"2018","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/30307897","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20940006","id":"PMC_20940006","title":"Identification of mutations in the lipoprotein lipase (LPL) and apolipoprotein C-II (APOC2) genes using denaturing high performance liquid chromatography (DHPLC).","date":"2010","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20940006","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40983153","id":"PMC_40983153","title":"High-throughput screening reveals paeoniflorin's efficacy against Apoc2-deficient hypertriglyceridemia via HNF4A/PPARA/LDLR.","date":"2025","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40983153","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41296440","id":"PMC_41296440","title":"APOC2 Promotes Clear Cell Renal Cell Carcinoma Progression via Activation of the JAK-STAT Signaling Pathway.","date":"2025","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/41296440","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.08.01.667173","title":"Nanoparticle-enabled plasma proteomics of a mouse atherosclerosis model","date":"2025-08-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.01.667173","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.07.01.662592","title":"Haplotype-Resolved DNA Methylation at the<i>APOE</i>Locus identifies Allele-Specific Epigenetic Signatures Relevant to Alzheimer’s Disease Risk","date":"2025-07-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.01.662592","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.05.24.655950","title":"Robust Serum Proteomic Signatures of APOE2","date":"2025-05-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.24.655950","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.10.25323519","title":"A Quantitative Trait Locus for Reduced Microglial<i>APOE</i>Expression Associates with Reduced Cerebral Amyloid Angiopathy","date":"2025-03-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.10.25323519","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.05.29.596423","title":"Directly Measuring Atherogenic Lipoprotein Kinetics in Zebrafish with the Photoconvertible LipoTimer Reporter","date":"2024-05-31","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.29.596423","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"20686565","id":"PMC_20686565","title":"Biological, clinical and population relevance of 95 loci for blood lipids.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20686565","citation_count":2873,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18193044","id":"PMC_18193044","title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193044","citation_count":1130,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060906","id":"PMC_19060906","title":"Common variants at 30 loci contribute to polygenic dyslipidemia.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19060906","citation_count":1113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391210","id":"PMC_10391210","title":"Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391210","citation_count":769,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16968945","id":"PMC_16968945","title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.","date":"2006","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16968945","citation_count":579,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4345202","id":"PMC_4345202","title":"Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man.","date":"1973","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/4345202","citation_count":514,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22286219","id":"PMC_22286219","title":"Genome-wide association study identifies multiple loci influencing human serum metabolite levels.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22286219","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26871637","id":"PMC_26871637","title":"Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26871637","citation_count":423,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20714348","id":"PMC_20714348","title":"Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits.","date":"2010","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20714348","citation_count":363,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20864672","id":"PMC_20864672","title":"Genetic variants influencing circulating lipid levels and risk of coronary artery disease.","date":"2010","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20864672","citation_count":351,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11752456","id":"PMC_11752456","title":"Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11752456","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11579204","id":"PMC_11579204","title":"Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.","date":"2001","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11579204","citation_count":283,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4020294","id":"PMC_4020294","title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver.","date":"1985","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/4020294","citation_count":278,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11162594","id":"PMC_11162594","title":"Apolipoprotein specificity for lipid efflux by the human ABCAI transporter.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11162594","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15174051","id":"PMC_15174051","title":"An investigation into the human serum \"interactome\".","date":"2004","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/15174051","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11751863","id":"PMC_11751863","title":"Macromolecular crowding accelerates amyloid formation by human apolipoprotein C-II.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11751863","citation_count":227,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1917954","id":"PMC_1917954","title":"Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1917954","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12032151","id":"PMC_12032151","title":"Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12032151","citation_count":198,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"194244","id":"PMC_194244","title":"Primary structure of very low density apolipoprotein C-II of human plasma.","date":"1977","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/194244","citation_count":166,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"270715","id":"PMC_270715","title":"Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II.","date":"1977","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/270715","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"182536","id":"PMC_182536","title":"Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase.","date":"1976","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/182536","citation_count":162,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16682745","id":"PMC_16682745","title":"Isolation and characterization of human apolipoprotein M-containing lipoproteins.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16682745","citation_count":161,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6328445","id":"PMC_6328445","title":"Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance.","date":"1984","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/6328445","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21090,"output_tokens":2499,"usd":0.050377},"stage2":{"model":"claude-opus-4-6","input_tokens":5833,"output_tokens":2146,"usd":0.124222},"total_usd":0.436769,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":34995,"output_tokens":5195,"usd":0.091455},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8987,"output_tokens":2755,"usd":0.170715}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2023,\n      \"finding\": \"APOC2's C-terminal α-helix binds to regions of LPL surrounding the catalytic pocket, overlapping with the ANGPTL4 binding site but producing opposite conformational effects: APOC2 increases LPL thermal stability, protects it from unfolding, and stabilizes the lid-anchoring structures, thereby activating LPL catalysis.\",\n      \"method\": \"Hydrogen-deuterium exchange/mass spectrometry (HDX-MS) with thermal stability assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — HDX-MS structural mapping combined with functional thermal stability assays; single rigorous paper with orthogonal methods defining binding site and conformational mechanism\",\n      \"pmids\": [\"37094117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ApoC2 functions as an obligatory activator of lipoprotein lipase (LPL)-mediated triglyceride hydrolysis in vivo; CRISPR/Cas9 deletion of Apoc2 in hamsters causes severe hypertriglyceridemia that is fully rescued by AAV-mediated hApoC2 delivery, demonstrating ApoC2 is specifically required for LPL activation in plasma triglyceride clearance.\",\n      \"method\": \"CRISPR/Cas9 knockout in hamster with AAV rescue, plasma triglyceride measurement, medium-chain triglyceride diet intervention\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotype plus functional genetic rescue by AAV-hApoC2, multiple interventional approaches in a mammalian model\",\n      \"pmids\": [\"32562799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AAV-mediated delivery of human ApoC2 to ApoC2-deficient hamsters completely corrects severe hypertriglyceridemia in both adult and neonatal animals, confirming ApoC2 is the rate-limiting activating cofactor for LPL-dependent triglyceride clearance.\",\n      \"method\": \"AAV-hApoC2 gene delivery (jugular or orbital vein injection) in ApoC2-/- hamsters with lipid profile measurements\",\n      \"journal\": \"Molecular therapy. Methods & clinical development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional genetic rescue in vivo with well-defined phenotypic readout, corroborated by companion KO study\",\n      \"pmids\": [\"32802915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A missense variant R72T in APOC2 causes loss of functional apoC-II activity; molecular modeling predicted reduced lipid-binding affinity of the variant peptide, and in vitro studies of patient plasma confirmed absence of both functional apoC-II activity and detectable apoC-II protein.\",\n      \"method\": \"Molecular modeling, in vitro plasma functional assay for LPL activation, protein quantification\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional assay in patient plasma plus structural modeling; single study but two orthogonal approaches\",\n      \"pmids\": [\"28201738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"apoc2 knockout zebrafish display deficient plasma cholesterol esterification: hepatic expression of lcat (lecithin-cholesterol acyltransferase) and apolipoprotein A-I are dramatically reduced, resulting in elevated free cholesterol to cholesterol ester ratio, linking APOC2-dependent LPL activity to downstream HDL/LCAT function.\",\n      \"method\": \"apoc2 knockout zebrafish, in situ hybridization, qPCR, plasma lipid measurement; validated in human FCS patient plasma with LCAT activity assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO model with mechanistic follow-up (gene expression, enzyme activity) corroborated in human patient samples\",\n      \"pmids\": [\"28107429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-1275 directly targets the 3′ UTR of APOC2 mRNA in macrophages, suppressing APOC2 expression and inhibiting macrophage foam cell formation and ox-LDL uptake.\",\n      \"method\": \"Dual-luciferase reporter assay, RT-qPCR, macrophage foam cell formation assay in THP-1-derived macrophages\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter confirms direct 3′UTR targeting; functional cellular assay shows downstream consequence; single lab\",\n      \"pmids\": [\"31935511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-4510 directly targets APOC2 (confirmed by luciferase reporter assay); overexpression of miR-4510 suppresses APOC2 protein and mRNA, inhibits GIST cell proliferation, migration and invasion, and reduces phosphorylation of AKT and ERK1/2; APOC2 knockdown recapitulates these effects, placing APOC2 upstream of AKT/ERK signaling in GIST cells.\",\n      \"method\": \"Luciferase reporter assay, siRNA knockdown, overexpression, western blotting for pAKT and pERK1/2 in GIST cells\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct target validation by luciferase plus epistatic rescue experiments; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"31975384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FXR transcriptionally upregulates ApoC2 in beige adipocytes; ApoC2 overexpression in preadipocytes and beige adipocytes increases UCP1 and PGC1α expression, placing the FXR→ApoC2 axis upstream of UCP1-mediated thermogenesis and white adipose tissue browning.\",\n      \"method\": \"FXR agonist (farnesol) treatment, FXR/RXRα knockdown, ApoC2 overexpression in beige adipocytes and cold-exposed mice, western blotting and gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD and OE experiments with defined molecular phenotype in beige adipocytes and in vivo cold exposure; single lab but multiple genetic perturbations\",\n      \"pmids\": [\"39798876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"APOC2 knockdown in ccRCC cells reduces phosphorylation of JAK1/2 and STAT3 (without affecting total protein levels) and suppresses proliferation; STAT3 agonist Colivelin partially rescues viability after APOC2 knockdown, placing APOC2 upstream of JAK-STAT signaling in renal cell carcinoma.\",\n      \"method\": \"siRNA knockdown, western blotting for JAK/STAT phosphorylation, pharmacological rescue with STAT3 agonist, proliferation and apoptosis assays\",\n      \"journal\": \"Current issues in molecular biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single knockdown approach with partial rescue; no direct binding or upstream mechanism defined\",\n      \"pmids\": [\"41296440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A case of apoC-II deficiency was identified in which transcription of apoC-II mRNA was decreased (demonstrated in monocyte/macrophage culture and minigene reporter assay) without any rare variant in the APOC2 coding region, indicating that trans-acting factors or regulatory elements outside APOC2 control apoC-II expression levels.\",\n      \"method\": \"Monocyte/macrophage culture system for apoC-II mRNA quantification, minigene transcriptional reporter assay, Sanger sequencing of APOC2\",\n      \"journal\": \"Journal of atherosclerosis and thrombosis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single case with reporter assay evidence; mechanistic detail on the trans-acting regulator not defined\",\n      \"pmids\": [\"23470567\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOC2 encodes apolipoprotein C-II, whose C-terminal α-helix binds directly to LPL at a site overlapping the ANGPTL4 inhibitor site, stabilizing LPL's lid-anchoring structures and catalytic conformation to activate triglyceride hydrolysis from chylomicrons and VLDL; loss of APOC2 causes severe hypertriglyceridemia that is fully rescued by AAV-delivered hApoC2, and APOC2 expression is regulated post-transcriptionally by miR-1275 and miR-4510, and transcriptionally by FXR in beige adipocytes where it promotes UCP1-mediated thermogenesis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1977,\n      \"finding\": \"The C-terminal region of apoC-II (residues 55–78) is both necessary and sufficient for maximal activation of lipoprotein lipase (LPL); the fragment 60–78 activates LPL ~4-fold, fragment 55–78 activates ~12-fold (comparable to intact apoC-II at ~13-fold), while removal of the three C-terminal residues (Gly-Glu-Glu) abolishes >95% of activation activity.\",\n      \"method\": \"In vitro LPL activation assay using cyanogen bromide fragments and synthetic peptides of apoC-II\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro assay with multiple synthetic fragments and mutagenesis-equivalent deletions; foundational study with >100 citations\",\n      \"pmids\": [\"270715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1977,\n      \"finding\": \"ApoC-II has a primary structure of 78 amino acid residues (lacking cysteine, cystine, and histidine), establishing it as the activator protein of LPL in very low density lipoproteins.\",\n      \"method\": \"Protein purification, cyanogen bromide digestion, and sequential amino acid sequencing of tryptic/CNBr peptides\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein sequencing, foundational structural determination, >100 citations\",\n      \"pmids\": [\"194244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1973,\n      \"finding\": \"During alimentary lipemia, apoC-II (the LPL activator protein) transfers specifically from HDL to chylomicrons, with chylomicron apoC-II concentration directly proportional to particle diameter; HDL apoC-II decreases correspondingly, demonstrating a dynamic exchange of apoC-II between lipoprotein classes.\",\n      \"method\": \"Ultracentrifugal fractionation and polyacrylamide gel electrophoresis of lipoprotein subfractions from human subjects pre- and post-fat meal\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical fractionation in human subjects, replicated across multiple time points, >500 citations\",\n      \"pmids\": [\"4345202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"The cDNA for apoC-II was isolated and sequenced, identifying a 22-amino-acid signal peptide and determining relative liver mRNA abundance, establishing the molecular basis for apoC-II biosynthesis.\",\n      \"method\": \"cDNA cloning, nucleotide sequencing, and Northern blot mRNA quantification\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct cDNA sequencing and mRNA abundance measurement; >100 citations\",\n      \"pmids\": [\"6328445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"ApoC-II (along with apoC-I and apoC-III isoforms) inhibits the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver; this inhibition is independent of apoE and applies to both chylomicron remnants and VLDL remnants. Preferential loss of apoC-II during remnant formation may regulate termination of triglyceride hydrolysis.\",\n      \"method\": \"Isolated perfused rat liver assay with exogenous addition of individual human C apolipoproteins to chylomicrons and VLDL remnants\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted perfused organ system with defined apolipoprotein additions; >250 citations\",\n      \"pmids\": [\"4020294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"ApoC-II inhibits apoE-dependent cellular uptake and degradation of triglyceride-rich lipoproteins via the LDL receptor pathway; the apoE:apoC ratio on the lipoprotein surface determines the extent of receptor-mediated uptake. ApoC-II does not affect LDL (apoB-100-mediated) metabolism significantly, demonstrating specificity for the apoE-dependent interaction.\",\n      \"method\": \"Cultured human skin fibroblast uptake/degradation assays using VLDL and IDL with exogenous recombinant apoE-3 and individual apoC species; monoclonal antibody blocking of apoB-100 vs. apoE\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — cell-based reconstitution with defined protein additions, antibody-blocking specificity controls; >200 citations\",\n      \"pmids\": [\"1917954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Farnesoid X receptor (FXR) directly induces APOC2 transcription by binding two FXR response elements within hepatic control regions (HCR-1 and HCR-2) located 11 kb and 22 kb upstream of the apoC-II transcription start site; FXR/RXR heterodimers bind these elements by EMSA, and luciferase reporter assays confirm transactivation. In vivo, hepatic apoC-II mRNA increases in mice fed cholic acid (an FXR ligand), and this induction is absent in FXR-null mice, linking bile acid signaling to plasma triglyceride lowering via apoC-II.\",\n      \"method\": \"Suppression subtractive hybridization, retroviral FXR expression in HepG2 cells, EMSA with recombinant FXR/RXR, luciferase reporter assays, mouse dietary cholic acid feeding, FXR knockout mice\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (EMSA, reporter assay, in vivo KO model); >250 citations\",\n      \"pmids\": [\"11579204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ABCA1 mediates cholesterol and phospholipid efflux using apoC-II (as well as apoA-I, apoA-II, apoA-IV, apoC-I, apoC-III, apoE) as acceptors; apoC-II promotes greater than 3-fold increase in lipid efflux from ABCA1-expressing cells compared to controls, indicating apoC-II can serve as a lipid acceptor for ABCA1-mediated reverse cholesterol transport.\",\n      \"method\": \"Stable transfection of ABCA1-GFP in HeLa cells, cholesterol and phospholipid efflux assays, specific binding assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean cellular assay with defined protein acceptors; single lab but multiple apolipoproteins tested as controls; >250 citations\",\n      \"pmids\": [\"11162594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ApoC-II forms amyloid fibers in lipid-free solutions under physiological conditions; macromolecular crowding (inert polymer dextran T10) significantly accelerates amyloid formation rate and extent via nonspecific volume exclusion, without altering secondary structure, fiber morphology, or dye-binding capacity of the fibers.\",\n      \"method\": \"Solution turbidity, thioflavin T reactivity, sedimentation assays, analytical ultracentrifugation, secondary structure analysis; quantitative modeling of volume exclusion\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biophysical assays with quantitative mechanistic modeling; >200 citations\",\n      \"pmids\": [\"11751863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The APOE/C-I/C-IV/C-II gene cluster is transcriptionally regulated by liver X receptors (LXRα/β) in macrophages; LXR/RXR ligands induce apoC-II mRNA 2–14-fold, this induction requires the LXR response elements in multienhancers ME.1 and ME.2 of the apoC-II promoter-reporter, and is abolished in LXRα/β double-null macrophages. ApoC-II protein co-localizes with macrophages within murine arterial lesions.\",\n      \"method\": \"Microarray, Northern blot, LXRα/β knockout murine macrophages, luciferase reporter assays with ME.1/ME.2 enhancer elements, immunohistochemistry of atherosclerotic lesions\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO validation plus reporter assays and in vivo localization; >190 citations\",\n      \"pmids\": [\"12032151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"APOC2 knockout zebrafish (apoc2−/−) exhibit deficient plasma cholesterol esterification: significantly elevated free cholesterol to cholesterol ester ratio (FC/CE) compared to wild type, accompanied by dramatically decreased hepatic LCAT expression and apoA-I expression. This defect persists on low-fat diet even when triglycerides normalize, and is recapitulated in human FCS patients with APOC2 or LPL deficiency, revealing a novel link between LPL cofactor activity and LCAT-mediated cholesterol esterification.\",\n      \"method\": \"apoc2 knockout zebrafish, plasma FC/CE measurements, in situ hybridization, qPCR of lcat and apoA-I, LCAT activity assay in human FCS patient plasma, lipidomics of chylomicron-depleted fractions\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO model plus human patient validation with orthogonal biochemical assays\",\n      \"pmids\": [\"28107429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ApoC2 is an obligatory activator of LPL for plasma triglyceride hydrolysis; CRISPR/Cas9 deletion of Apoc2 in golden Syrian hamsters causes severe hypertriglyceridemia that cannot be corrected by lipid-lowering medications but is fully reversed by AAV-hApoC2 gene therapy, demonstrating that ApoC2 is essential and sufficient for LPL-mediated triglyceride metabolism in a mammalian model.\",\n      \"method\": \"CRISPR/Cas9 Apoc2 knockout hamster, AAV-hApoC2 gene therapy rescue, lipid profile measurements, diet intervention, neonatal serum infusion rescue\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — complete genetic KO with defined molecular rescue in mammalian model\",\n      \"pmids\": [\"32562799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-1275 directly targets the 3′ UTR of ApoC2 mRNA in macrophages, suppressing ApoC2 protein expression; ApoC2 knockdown inhibits macrophage foam cell formation by reducing ox-LDL uptake, and ApoC2 overexpression promotes foam cell formation, placing ApoC2 downstream of miR-1275 in macrophage lipid accumulation relevant to ischemic stroke pathogenesis.\",\n      \"method\": \"Dual-luciferase reporter assay, miRNA microarray, quantitative RT-PCR, THP-1 macrophage foam cell assay with ox-LDL uptake measurement, siRNA knockdown\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — luciferase reporter plus functional cellular assays; single lab\",\n      \"pmids\": [\"31935511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-4510 directly targets APOC2 (confirmed by luciferase reporter assay); APOC2 knockdown in GIST cells suppresses cell proliferation, migration, and invasion, reduces AKT and ERK1/2 phosphorylation, and decreases MMP2/MMP9 expression, identifying APOC2 as a pro-tumorigenic factor acting through PI3K/AKT and MAPK/ERK signaling in gastrointestinal stromal tumors.\",\n      \"method\": \"Luciferase reporter assay, siRNA knockdown of APOC2, cell proliferation/migration/invasion assays, Western blotting for p-AKT, p-ERK1/2, MMP2, MMP9\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — luciferase confirmation plus functional KD phenotype with pathway readouts; single lab\",\n      \"pmids\": [\"31975384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ApoC-II's C-terminal α-helix binds to regions of LPL surrounding the catalytic pocket (lid-anchoring structures), overlapping with the ANGPTL4 binding site on LPL. Unlike ANGPTL4, which destabilizes LPL's lid-anchoring regions and promotes irreversible unfolding, APOC2 binding increases LPL thermal stability and protects these regions from unfolding, providing a molecular mechanism for APOC2-mediated LPL activation through conformational stabilization of the active site.\",\n      \"method\": \"Hydrogen-deuterium exchange mass spectrometry (HDX-MS) with thermal stability assays comparing APOC2 vs. ANGPTL4 binding to LPL\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural/biophysical HDX-MS with direct comparison of activator vs. inhibitor binding to same site; mechanistically rigorous\",\n      \"pmids\": [\"37094117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"APOC2 expression level defines distinct alveolar macrophage superclusters (families) in human bronchoalveolar lavage; differential APOC2/IFI27 expression distinguishes four AM supercluster identities, each containing functionally specialized subclusters, indicating APOC2 marks a transcriptionally and functionally distinct state in resident lung macrophages.\",\n      \"method\": \"Single-cell RNA sequencing of 113,213 bronchoalveolar lavage cells, TotalSeq protein surface marker validation, projection of external AM datasets\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — scRNA-seq classification without direct functional manipulation of APOC2 in macrophages\",\n      \"pmids\": [\"35820705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In bovine adipocytes, miR-107 directly targets APOC2 (confirmed by luciferase reporter assay); APOC2 knockdown (siRNA) suppresses adipocyte differentiation and lipid droplet accumulation, while miR-107 overexpression (which reduces APOC2) similarly inhibits adipogenesis, establishing APOC2 as a positive regulator of bovine adipocyte differentiation and lipogenesis downstream of miR-107.\",\n      \"method\": \"Luciferase reporter assay, agomiR/antiagomiR transfection, siRNA-APOC2 knockdown, Oil Red O staining, CCK-8, EdU proliferation assay, RT-qPCR, Western blotting\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — luciferase confirmation plus functional KD in bovine cells; single lab, non-human model\",\n      \"pmids\": [\"36011378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FXR activation upregulates ApoC2 expression in beige adipocytes (but not mature white adipocytes); ApoC2 overexpression in preadipocytes and beige adipocytes increases UCP1 and PGC1α expression, while FXR knockdown reduces ApoC2 along with UCP1, PGC1α, and PRDM16, placing ApoC2 downstream of FXR in a pathway promoting white adipose tissue browning and thermogenesis.\",\n      \"method\": \"FXR agonist (farnesol) treatment, siRNA knockdown of FXR and RXRα, ApoC2 overexpression in preadipocytes and beige adipocytes, Western blotting and RT-qPCR for beige/thermogenic markers, cold-exposure mouse model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function in cells plus in vivo cold exposure; single lab, mechanism partially established\",\n      \"pmids\": [\"39798876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"APOC2 knockdown in clear cell renal cell carcinoma (ccRCC) cell lines suppresses proliferation, colony formation, migration, and invasion while promoting apoptosis; silencing APOC2 reduces phosphorylation of JAK1/2 and STAT3 without affecting total protein levels, and the STAT3 agonist Colivelin partially rescues viability and apoptosis caused by APOC2 knockdown, indicating APOC2 promotes ccRCC progression at least partly through JAK-STAT pathway activation.\",\n      \"method\": \"siRNA knockdown of APOC2 in ccRCC cell lines, proliferation/colony/migration/invasion/apoptosis assays, Western blotting for p-JAK1/2 and p-STAT3, functional rescue with Colivelin (STAT3 agonist), gene set enrichment analysis\",\n      \"journal\": \"Current issues in molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — KD with defined pathway readout and partial rescue; single lab, cellular context non-canonical for APOC2\",\n      \"pmids\": [\"41296440\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ApoC-II (APOC2) is a 78-residue plasma apolipoprotein whose C-terminal α-helix (residues ~55–78) directly binds and stabilizes the lid-anchoring regions of lipoprotein lipase (LPL), increasing LPL thermal stability and activating triglyceride hydrolysis of VLDL and chylomicrons; it also inhibits apoE-dependent hepatic remnant uptake via the LDL receptor, transfers dynamically between HDL and triglyceride-rich lipoproteins during alimentary lipemia, is transcriptionally induced by FXR (via hepatic control region response elements) and by LXR in macrophages, forms amyloid fibers under crowded conditions, and has emerging roles in cholesterol esterification, adipose browning (via FXR-ApoC2-UCP1 axis), and cellular signaling (JAK-STAT) in non-classical contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"Apolipoprotein C-II (APOC2) is the obligatory protein cofactor for lipoprotein lipase (LPL), required for efficient triglyceride hydrolysis from chylomicrons and VLDL and thus for systemic triglyceride clearance. Its C-terminal α-helix binds LPL near the catalytic pocket—overlapping the ANGPTL4 inhibitory site—and stabilizes the enzyme's lid-anchoring structures and active conformation, increasing LPL thermal stability and catalytic activity [PMID:37094117]. Loss-of-function mutations or genetic deletion of APOC2 cause severe hypertriglyceridemia that is fully corrected by AAV-mediated delivery of human APOC2, and secondary effects include impaired LCAT-dependent cholesterol esterification [PMID:32562799, PMID:28107429]. Beyond lipoprotein metabolism, FXR transcriptionally induces APOC2 in beige adipocytes where it promotes UCP1-mediated thermogenesis, and APOC2 expression is post-transcriptionally regulated by miR-1275 and miR-4510 [PMID:39798876, PMID:31935511, PMID:31975384].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"The discovery that apoC-II deficiency can arise from reduced transcription without coding-region mutations established that APOC2 expression is controlled by trans-acting regulatory factors, opening questions about its transcriptional regulation.\",\n      \"evidence\": \"Monocyte/macrophage culture and minigene reporter assay in a single patient lacking coding-region variants\",\n      \"pmids\": [\"23470567\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"The identity of the trans-acting regulator(s) was not determined\",\n        \"Single case study without independent replication\",\n        \"No genome-wide search for regulatory variants was performed\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of a pathogenic APOC2 missense variant (R72T) and characterization of apoc2-knockout zebrafish expanded the phenotypic spectrum of APOC2 deficiency beyond hypertriglyceridemia to include impaired LCAT-dependent cholesterol esterification, revealing that LPL activation by APOC2 has downstream consequences for HDL metabolism.\",\n      \"evidence\": \"Patient plasma functional assay and molecular modeling for R72T; apoc2 KO zebrafish with in situ hybridization, qPCR, and plasma lipid measurement validated in human FCS patient plasma\",\n      \"pmids\": [\"28201738\", \"28107429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the LCAT effect is direct or secondary to altered lipoprotein remodeling was not resolved\",\n        \"Structural basis for R72T loss of function was modeled but not experimentally determined\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR-mediated Apoc2 knockout in hamsters and AAV-hApoC2 rescue definitively established APOC2 as the rate-limiting obligatory activator of LPL-dependent triglyceride clearance in a mammalian system, providing the first complete genetic loss-and-rescue proof in vivo.\",\n      \"evidence\": \"CRISPR/Cas9 Apoc2 KO hamsters with AAV-hApoC2 rescue via jugular/orbital vein injection; plasma triglyceride measurement\",\n      \"pmids\": [\"32562799\", \"32802915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Tissue-specific contributions of APOC2 to LPL activation (e.g., muscle vs. adipose) were not dissected\",\n        \"Long-term safety and durability of AAV rescue was not fully characterized\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of miR-1275 and miR-4510 as direct post-transcriptional repressors of APOC2 revealed that APOC2 expression is tuned by microRNAs in macrophages and GIST cells, with downstream effects on foam cell formation and AKT/ERK signaling respectively.\",\n      \"evidence\": \"Dual-luciferase 3′UTR reporter assays confirming direct targeting; siRNA knockdown and overexpression with western blotting in THP-1 macrophages and GIST cell lines\",\n      \"pmids\": [\"31935511\", \"31975384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether miR-1275 or miR-4510 regulate APOC2 in hepatocytes or in vivo is unknown\",\n        \"The mechanism by which APOC2 activates AKT/ERK signaling in GIST cells independent of LPL was not defined\",\n        \"No in vivo validation of the miRNA-APOC2 axes was performed\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"HDX-MS mapping of the APOC2–LPL interaction revealed the molecular mechanism of cofactor activation: the APOC2 C-terminal helix binds LPL at sites overlapping the ANGPTL4 inhibitory interface and stabilizes lid-anchoring structures to maintain the enzyme in a catalytically competent conformation.\",\n      \"evidence\": \"Hydrogen-deuterium exchange mass spectrometry with thermal stability assays on purified LPL–APOC2 complexes\",\n      \"pmids\": [\"37094117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"A high-resolution co-crystal or cryo-EM structure of the APOC2–LPL complex is still lacking\",\n        \"Whether APOC2 and ANGPTL4 compete directly on lipoprotein-bound LPL in vivo was not tested\",\n        \"Contribution of the APOC2 N-terminal domain to activation was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The discovery that FXR transcriptionally activates APOC2 in beige adipocytes to drive UCP1-mediated thermogenesis revealed a non-canonical, non-hepatic function for APOC2 linking bile acid signaling to adaptive thermogenesis.\",\n      \"evidence\": \"FXR agonist treatment, FXR/RXRα knockdown, ApoC2 overexpression in beige adipocytes and cold-exposed mice with UCP1/PGC1α western blotting\",\n      \"pmids\": [\"39798876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the thermogenic effect requires LPL activation or represents an LPL-independent function is unknown\",\n        \"The direct FXR binding site in the APOC2 promoter was not mapped\",\n        \"In vivo relevance of adipocyte-derived APOC2 vs. hepatocyte-derived APOC2 was not delineated\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include whether APOC2's reported roles in cancer signaling (AKT/ERK, JAK-STAT) operate through LPL-dependent or -independent mechanisms, the atomic-resolution structure of the APOC2–LPL complex, and the physiological significance of adipocyte-expressed APOC2 in thermogenesis relative to its canonical hepatic/lipoprotein function.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No atomic-resolution structure of the APOC2–LPL complex exists\",\n        \"LPL-independent signaling functions of APOC2 lack mechanistic explanation\",\n        \"Tissue-specific APOC2 contributions have not been dissected with conditional knockout models\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"LPL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Apolipoprotein C-II is a 78-residue exchangeable apolipoprotein that serves as the obligatory cofactor for lipoprotein lipase (LPL)-mediated hydrolysis of triglycerides in VLDL and chylomicrons. Its C-terminal α-helix (residues 55–78) binds LPL's lid-anchoring regions near the catalytic pocket, increasing LPL thermal stability and protecting against ANGPTL4-induced unfolding, thereby activating triglyceride hydrolysis; the terminal Gly-Glu-Glu residues are critical for this activation [PMID:270715, PMID:37094117]. ApoC-II transfers dynamically from HDL to triglyceride-rich lipoproteins during alimentary lipemia, inhibits apoE-dependent hepatic remnant uptake via the LDL receptor pathway, and is transcriptionally induced by FXR in liver and LXR in macrophages [PMID:4345202, PMID:1917954, PMID:11579204, PMID:12032151]. Genetic ablation in hamsters causes severe hypertriglyceridemia fully rescued by AAV-delivered human APOC2, and loss of APOC2 in zebrafish additionally impairs LCAT-mediated cholesterol esterification, revealing roles beyond triglyceride catabolism [PMID:32562799, PMID:28107429].\",\n  \"teleology\": [\n    {\n      \"year\": 1973,\n      \"claim\": \"Establishing that apoC-II is not statically bound to one lipoprotein class but dynamically redistributes from HDL to chylomicrons during fat absorption answered how the activator reaches its substrate particles in vivo.\",\n      \"evidence\": \"Ultracentrifugal fractionation and gel electrophoresis of human lipoproteins pre- and post-fat meal\",\n      \"pmids\": [\"4345202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism governing transfer kinetics and directionality was not defined\", \"Whether transfer is passive equilibrium or protein-mediated was not distinguished\"]\n    },\n    {\n      \"year\": 1977,\n      \"claim\": \"Determination of apoC-II's 78-residue primary structure and mapping of the LPL-activating domain to the C-terminal helix (residues 55–78, with terminal Gly-Glu-Glu essential) resolved which portion of the protein is functionally critical and established the minimal activating unit.\",\n      \"evidence\": \"Protein sequencing plus in vitro LPL activation assays with synthetic and CNBr-derived peptide fragments\",\n      \"pmids\": [\"194244\", \"270715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how the C-terminal helix contacts LPL was unknown\", \"Role of the N-terminal domain in lipid binding versus activation was not separated\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Showing that apoC-II inhibits hepatic uptake of triglyceride-rich lipoprotein remnants—independent of its LPL-activating role—revealed a second function: modulating receptor-mediated clearance by competing with apoE on the particle surface.\",\n      \"evidence\": \"Perfused rat liver assay with exogenous addition of purified apoC-II to remnant particles; cell-based fibroblast uptake assays with antibody blocking (1991 confirmation)\",\n      \"pmids\": [\"4020294\", \"1917954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether inhibition is purely steric displacement of apoE or involves receptor conformational effects was not resolved\", \"Relative in vivo contribution of uptake inhibition versus LPL activation to triglyceride homeostasis was not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of FXR-responsive elements in the apoC-II hepatic control regions and LXR-responsive multienhancers in macrophages established how bile acid and oxysterol signaling transcriptionally control APOC2 expression in distinct cell types.\",\n      \"evidence\": \"EMSA, luciferase reporters, FXR-null mice with dietary cholic acid (FXR); LXRα/β double-KO macrophages with ligand treatment (LXR)\",\n      \"pmids\": [\"11579204\", \"12032151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of FXR versus LXR to circulating apoC-II levels in humans was not determined\", \"Post-transcriptional regulation was not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The discovery that lipid-free apoC-II readily forms amyloid fibrils under physiological conditions—accelerated by macromolecular crowding—raised the question of whether apoC-II amyloidosis occurs in vivo and whether lipid dissociation is a pathogenic event.\",\n      \"evidence\": \"Thioflavin T fluorescence, turbidity, analytical ultracentrifugation, and quantitative crowding modeling\",\n      \"pmids\": [\"11751863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo evidence that apoC-II amyloid deposits contribute to disease\", \"Whether lipoprotein binding constitutively suppresses amyloid nucleation was not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Zebrafish apoc2 knockouts revealed an unexpected requirement for apoC-II in LCAT-mediated cholesterol esterification, extending its metabolic role beyond triglyceride hydrolysis and linking it to HDL maturation.\",\n      \"evidence\": \"CRISPR apoc2-KO zebrafish with plasma FC/CE ratio measurement, qPCR of lcat/apoA-I, validated in human familial chylomicronemia syndrome patients\",\n      \"pmids\": [\"28107429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the cholesterol esterification defect is a direct apoC-II effect or secondary to chronic hypertriglyceridemia was not resolved\", \"Mechanism linking apoC-II to lcat transcription was not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"CRISPR-generated Apoc2-knockout hamsters confirmed apoC-II as the indispensable LPL cofactor in a mammalian model: severe hypertriglyceridemia was refractory to lipid-lowering drugs but fully corrected by AAV-hApoC2 gene therapy, providing proof-of-concept for gene-replacement treatment.\",\n      \"evidence\": \"Apoc2-KO hamster model with AAV-hApoC2 rescue, lipid profiling, dietary and pharmacological interventions\",\n      \"pmids\": [\"32562799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety and durability of AAV-mediated correction were not assessed\", \"Effect of gene therapy on cholesterol esterification phenotype was not examined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"HDX-MS revealed the structural mechanism of LPL activation: apoC-II's C-terminal helix binds LPL's lid-anchoring regions overlapping the ANGPTL4 inhibitory site, stabilizing the catalytic pocket against thermal unfolding—explaining why apoC-II and ANGPTL4 act as opposing regulators at the same site.\",\n      \"evidence\": \"Hydrogen-deuterium exchange mass spectrometry comparing apoC-II and ANGPTL4 binding to LPL, with thermal stability assays\",\n      \"pmids\": [\"37094117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full atomic-resolution co-structure of the apoC-II–LPL complex is not yet available\", \"Whether additional LPL-binding partners modulate the apoC-II versus ANGPTL4 competition in vivo is unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placing apoC-II downstream of FXR in beige adipocytes as a promoter of UCP1/PGC1α expression expanded its biology to thermogenesis, while evidence in cancer cells suggested non-canonical JAK-STAT signaling roles, raising the question of whether apoC-II has cell-autonomous signaling functions distinct from lipoprotein metabolism.\",\n      \"evidence\": \"FXR agonist treatment and siRNA in beige adipocytes with thermogenic marker readouts; APOC2 knockdown in ccRCC cells with p-JAK1/2 and p-STAT3 Western blots and STAT3-agonist rescue\",\n      \"pmids\": [\"39798876\", \"41296440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether apoC-II acts as a secreted autocrine/paracrine ligand or intracellularly in these contexts is unknown\", \"JAK-STAT activation mechanism—direct receptor engagement versus indirect lipid signaling—is not defined\", \"Independent replication of non-canonical signaling roles is needed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution co-crystal or cryo-EM structure of the apoC-II–LPL complex is still lacking, the receptor or signaling mechanism underlying apoC-II's reported cell-autonomous effects in non-hepatic tissues remains unidentified, and whether apoC-II amyloid formation has pathological significance in vivo is unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No atomic co-structure of apoC-II–LPL complex\", \"No identified receptor for putative cell-autonomous apoC-II signaling\", \"In vivo relevance of apoC-II amyloidosis not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5, 14]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 7]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 11, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 2, 4, 11]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 4, 5, 10, 11, 14]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [2, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 9, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LPL\", \"ANGPTL4\", \"APOE\", \"ABCA1\", \"FXR\", \"LCAT\"],\n    \"other_free_text\": []\n  }\n}\n```"}